These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38677159)

  • 1. An evaluation of the cost-effectiveness of population genetic screening for familial hypercholesterolemia in US patients.
    Hendy LE; Spees LP; Tak C; Carpenter DM; Thomas KC; Roberts MC
    Atherosclerosis; 2024 Jun; 393():117541. PubMed ID: 38677159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.
    Nherera L; Marks D; Minhas R; Thorogood M; Humphries SE
    Heart; 2011 Jul; 97(14):1175-81. PubMed ID: 21685482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.
    McKay AJ; Hogan H; Humphries SE; Marks D; Ray KK; Miners A
    Atherosclerosis; 2018 Aug; 275():434-443. PubMed ID: 29937236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.
    Pelczarska A; Jakubczyk M; Jakubiak-Lasocka J; Banach M; Myśliwiec M; Gruchała M; Niewada M
    Atherosclerosis; 2018 Mar; 270():132-138. PubMed ID: 29407882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States.
    Chen CX; Hay JW
    Int J Cardiol; 2015 Feb; 181():417-24. PubMed ID: 25569270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of searching electronic health records and cascade testing to identify and diagnose familial hypercholesterolaemia in England and Wales.
    Crosland P; Maconachie R; Buckner S; McGuire H; Humphries SE; Qureshi N
    Atherosclerosis; 2018 Aug; 275():80-87. PubMed ID: 29879685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2022; 22(3):1-155. PubMed ID: 36158868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring Costs of Cardiovascular Disease Prevention for Patients with Familial Hypercholesterolemia in Administrative Claims Data.
    Passero LE; Roberts MC
    High Blood Press Cardiovasc Prev; 2024 Mar; 31(2):215-219. PubMed ID: 38308804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia.
    Ademi Z; Watts GF; Pang J; Sijbrands EJ; van Bockxmeer FM; O'Leary P; Geelhoed E; Liew D
    J Clin Lipidol; 2014; 8(4):390-400. PubMed ID: 25110220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States.
    Spencer SJ; Jones LK; Guzauskas GF; Hao J; Williams MS; Peterson JF; Veenstra DL
    J Clin Lipidol; 2022; 16(5):667-675. PubMed ID: 35961838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis.
    Qureshi N; Woods B; Neves de Faria R; Saramago Goncalves P; Cox E; Leonardi Bee J; Condon L; Weng S; Akyea RK; Iyen B; Roderick P; Humphries SE; Rowlands W; Watson M; Haralambos K; Kenny R; Datta D; Miedzybrodzka Z; Byrne C; Kai J
    Health Technol Assess; 2023 Oct; 27(16):1-140. PubMed ID: 37924278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
    Ademi Z; Norman R; Pang J; Liew D; Zoungas S; Sijbrands E; Ference BA; Wiegman A; Watts GF
    Atherosclerosis; 2020 Jul; 304():1-8. PubMed ID: 32526542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands.
    Wonderling D; Umans-Eckenhausen MA; Marks D; Defesche JC; Kastelein JJ; Thorogood M
    Semin Vasc Med; 2004 Feb; 4(1):97-104. PubMed ID: 15199439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.
    Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; Hout BV
    Clin Ther; 2017 Apr; 39(4):771-786.e3. PubMed ID: 28366593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Cost-effectiveness of Genetic Screening for Familial Hypercholesterolemia: a Systematic Review.
    Rosso A; Pitini E; D'Andrea E; Massimi A; De Vito C; Marzuillo C; Villari P
    Ann Ig; 2017; 29(5):464-480. PubMed ID: 28715059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic testing for familial hypercholesterolemia: Impact on diagnosis, treatment and cardiovascular risk.
    Lee S; Akioyamen LE; Aljenedil S; Rivière JB; Ruel I; Genest J
    Eur J Prev Cardiol; 2019 Aug; 26(12):1262-1270. PubMed ID: 30755017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK.
    Kerr M; Pears R; Miedzybrodzka Z; Haralambos K; Cather M; Watson M; Humphries SE
    Eur Heart J; 2017 Jun; 38(23):1832-1839. PubMed ID: 28387827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DIAgnosis and Management Of familial hypercholesterolemia in a Nationwide Design (DIAMOND-FH): Prevalence in Switzerland, clinical characteristics and the diagnostic value of clinical scores.
    Miserez AR; Martin FJ; Spirk D
    Atherosclerosis; 2018 Oct; 277():282-288. PubMed ID: 30270060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
    Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
    Clin Cardiol; 2016 Jun; 39(6):313-20. PubMed ID: 27092712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.